Stay updated with breaking news from Nasdaq Repl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group (NASDAQ:REPL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of […]
Replimune Group (NASDAQ:REPL – Get Rating) had its price target reduced by Piper Sandler from $52.00 to $44.00 in a report issued on Thursday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 201.16% from the stock’s previous close. A number of other brokerages have also recently commented on REPL. BMO […]
Replimune Group (NASDAQ:REPL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s […]
Replimune Group (NASDAQ:REPL – Get Rating) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $47.00 to $39.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 98.27% […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target […]